Glossary
Scientific, regulatory, and research terms explained
A
- Abbreviated New Drug Application (ANDA)— A simplified FDA submission for generic drug approval that relies on the reference drug's safety and efficacy data, requiring only demonstration of bioequivalence.
- Absolute Risk Reduction— The actual numerical difference in event rates between the treatment and control groups.
- Absorption Enhancer— A pharmaceutical excipient or technology that improves drug absorption across biological barriers.
- Accelerated Approval— An FDA pathway allowing earlier approval based on a surrogate endpoint reasonably likely to predict clinical benefit.
- Accelerated Stability Testing— Stability studies conducted at elevated temperature and humidity to predict long-term stability in a shorter timeframe.
- Acetylation— The addition of an acetyl group to a molecule, most commonly to the N-terminus of a peptide.
- Acetylcholine— A neurotransmitter critical for muscle activation, memory, and cognitive function.
- Achondroplasia— The most common form of dwarfism (1 in 15,000-40,000 births), caused by a gain-of-function FGFR3 mutation that inhibits bone growth.
- Acromegaly— A hormonal disorder caused by excess growth hormone from a pituitary adenoma, resulting in enlarged extremities and facial features.
- ACTH Stimulation Test— A diagnostic test for adrenal insufficiency where cosyntropin (synthetic ACTH fragment) is injected and cortisol response is measured.
- Active Comparator Trial— A clinical trial in which the control group receives an existing approved treatment rather than a placebo, enabling direct comparison of the new drug against current standard of care.
- Adaptive Immunity— The branch of the immune system that develops targeted responses to specific pathogens through T cells and B cells.
- Adaptive Trial Design— A clinical trial that allows pre-planned modifications to the study design based on interim data analysis, such as adjusting sample size, dropping ineffective dose arms, or modifying randomisation ratios.
- Addison's Disease— Primary adrenal insufficiency — failure of the adrenal glands to produce adequate cortisol and aldosterone.
- Adrenocorticotropic Hormone (ACTH)— A 39 amino acid peptide hormone produced by pituitary corticotroph cells that stimulates the adrenal cortex to produce cortisol.
- Adverse Event— Any unfavourable medical occurrence during or after treatment with a drug, regardless of whether it is caused by the drug.
- Adverse Event Reporting— The process of documenting and submitting reports of adverse drug reactions to regulatory authorities.
- Advisory Committee (FDA)— An independent panel of outside experts convened by the FDA to provide recommendations on drug approval decisions.
- Albumin Binding— A drug design strategy where a peptide is modified to reversibly bind to human serum albumin, the most abundant protein in blood plasma.
- Aldosterone— A steroid hormone produced by the adrenal cortex that regulates sodium and potassium balance and blood pressure.
- Allosteric Modulator— A substance that binds to a receptor at a site other than the primary (orthosteric) binding site and modifies the receptor's response to its natural ligand.
- Alpha-Melanocyte-Stimulating Hormone (α-MSH)— A 13 amino acid peptide derived from proopiomelanocortin (POMC) that stimulates melanin production in melanocytes through MC1R activation.
- Amidation— A chemical modification in which the C-terminal carboxyl group of a peptide is converted to an amide group.
- Amino Acid— An organic molecule that serves as the building block of peptides and proteins.
- Amino Acid Analysis— An analytical technique that determines the amino acid composition of a peptide by hydrolysing the peptide bonds and quantifying each amino acid present.
- Amino Acid Sequence— The specific order in which amino acids are arranged in a peptide or protein chain, read from the N-terminus to the C-terminus.
- Amino Acid Substitution— The replacement of one amino acid with another at a specific position in a peptide sequence.
- Amylase— A digestive enzyme produced primarily by the pancreas and salivary glands.
- Amylin— A 37 amino acid peptide hormone co-secreted with insulin from pancreatic beta cells that slows gastric emptying, suppresses glucagon, and promotes satiety.
- Analogue— A compound structurally similar to a naturally occurring molecule but deliberately modified to alter its properties such as potency, stability, or duration of action.
- Analytical Method Validation— The process of demonstrating that an analytical procedure is suitable for its intended purpose through assessment of accuracy, precision, specificity, linearity, range, and robustness.
- Anaphylaxis— A severe, potentially life-threatening allergic reaction occurring rapidly after drug exposure, involving multiple organ systems.
- Angiogenesis— The formation of new blood vessels from pre-existing vasculature, essential for wound healing and tissue repair but also exploited by tumours to support their growth.
- Angiotensin— A family of peptide hormones (angiotensin I, II, and III) central to blood pressure regulation.
- Animal Model— A non-human species used in research to study biological processes or diseases relevant to human health.
- Anterior Pituitary— The front lobe of the pituitary gland (adenohypophysis) that produces growth hormone, LH, FSH, ACTH, TSH, and prolactin in response to hypothalamic releasing hormones.
- Anti-Drug Antibody (ADA)— An antibody produced by a patient's immune system against a therapeutic peptide drug.
- Anti-Inflammatory Peptide— A peptide compound that reduces or modulates inflammatory responses.
- Antibiotic Resistance— The ability of bacteria to survive exposure to antibiotics that would normally kill or inhibit them.
- Antibody-Drug Conjugate (ADC)— A therapeutic combining a monoclonal antibody with a cytotoxic drug via a chemical linker.
- Antimicrobial Peptide— A peptide that kills or inhibits microorganisms.
- Antioxidant— A substance that neutralises reactive oxygen species and prevents oxidative damage to cells.
- Apoptosis— Programmed cell death — a controlled process by which cells self-destruct when damaged or no longer needed.
- Appetite Suppression— A reduction in the desire to eat, mediated by hormonal signals and neural circuits in the brain.
- Approved Drug— A pharmaceutical compound that has successfully completed clinical trials and received marketing authorisation from at least one major regulatory authority.
- Area Under the Curve (AUC)— A pharmacokinetic measure representing total drug exposure over time, calculated from a graph of drug concentration versus time.
- Aseptic Processing— A manufacturing method where the product, container, and closure are sterilised separately and then assembled under extremely clean conditions.
- Assisted Reproduction— Medical techniques used to achieve pregnancy, including IVF, intrauterine insemination, and ovulation induction.
- ATP Production— The generation of adenosine triphosphate, the primary energy currency of cells, primarily through oxidative phosphorylation in mitochondria.
- Atrial Natriuretic Peptide (ANP)— A 28 amino acid peptide hormone released by cardiac atrial cells in response to increased blood volume.
- Auto-Injector— A spring-loaded or motorised device for self-administration of injectable peptide drugs that automates needle insertion, drug delivery, and needle retraction.
- Autoimmune Disease— A condition where the immune system mistakenly attacks the body's own tissues.
- Autophagy— A cellular recycling process in which cells break down and recycle their own damaged components.
- Axonal Regeneration— The regrowth of damaged nerve cell extensions (axons).
B
- B Cell (B Lymphocyte)— A type of white blood cell that produces antibodies targeting specific pathogens.
- Bacteriostatic Water— Sterile water containing 0.
- Bariatric Pharmacotherapy— The use of medications to treat obesity, distinct from bariatric surgery.
- Barth Syndrome— A rare X-linked genetic disorder affecting cardiolipin production in mitochondrial membranes, causing cardiomyopathy, muscle weakness, and neutropenia.
- Basal Metabolic Rate— The minimum number of calories the body requires at rest to maintain basic life functions.
- Basket Trial— A clinical trial that tests a single drug in multiple diseases or conditions that share a common biological feature.
- Batch Number (Lot Number)— A unique identifier assigned to a specific production run of a pharmaceutical product.
- Beta Cell Function— The ability of pancreatic beta cells to produce and secrete insulin in response to glucose.
- Bioavailability— The proportion of an administered drug that reaches the systemic circulation and is available to produce its effect, expressed as a percentage.
- Biologic (Biological Product)— A pharmaceutical product derived from biological sources or produced using biological processes, including proteins, peptides, monoclonal antibodies, and vaccines.
- Biologics License Application (BLA)— A formal submission to the US FDA for approval of a biological product, including certain proteins and larger peptides produced by biological processes.
- Biomarker— A measurable biological indicator used to assess a disease state, predict treatment response, or monitor drug effects.
- Biosimilar— A biological product highly similar to an approved reference product with no clinically meaningful differences in safety, purity, or potency.
- Black Box Warning— The FDA's most serious safety warning, displayed in a bordered box at the top of prescribing information.
- Blinding (Masking)— The practice of concealing treatment assignment from participants, investigators, or both to prevent bias.
- Blood-Brain Barrier (BBB)— A highly selective membrane of tightly joined endothelial cells lining brain blood vessels that controls which substances enter the brain.
- Body Composition— The proportions of fat, muscle, bone, and water in the body.
- Body Mass Index (BMI)— A numerical value calculated from weight and height (kg/m²) used to categorise body weight status.
- Bolus Injection— A single, relatively large dose of a drug given as a rapid injection, as opposed to a slow infusion.
- Bone Healing— The natural repair process following bone fracture, involving inflammation, soft callus formation, hard callus formation, and remodelling over weeks to months.
- Bone Mineral Density (BMD)— A measurement of the mineral content in bone, used to diagnose osteoporosis and assess fracture risk.
- Boxed Warning— The most prominent safety warning in a drug's labelling, enclosed in a black border.
- BPC (Body Protection Compound)— A class of peptide sequences derived from a protective protein found in human gastric juice.
- Bradykinin Receptor— A receptor for bradykinin, a peptide that causes vasodilation, increases vascular permeability, and mediates pain and inflammation.
- Brain Natriuretic Peptide (BNP)— A peptide hormone released by cardiac ventricular cells in response to increased wall stress.
- Brain-Derived Neurotrophic Factor (BDNF)— The most abundant neurotrophin in the brain, critical for learning, memory, and synaptic plasticity.
- Breakthrough Therapy Designation— An FDA programme for drugs showing substantial improvement over available therapy based on preliminary clinical evidence.
C
- C-Reactive Protein (CRP)— A blood protein that rises rapidly in response to inflammation.
- C-Terminus— The end of a peptide or protein chain that has a free carboxyl group (-COOH).
- C-Type Natriuretic Peptide (CNP)— A natriuretic peptide found primarily in the brain and vascular endothelium that also plays a critical role in bone growth.
- Calcineurin Inhibitor— A class of immunosuppressive drugs that block calcineurin, a phosphatase essential for T cell activation.
- Calcitonin— A 32 amino acid peptide hormone produced by thyroid C-cells that lowers blood calcium by inhibiting bone resorption.
- Calcitonin Blood Test— A blood test measuring calcitonin levels, used primarily as a tumour marker for medullary thyroid carcinoma (MTC).
- Calcitonin Gene-Related Peptide (CGRP)— A 37 amino acid neuropeptide produced by alternative splicing of the calcitonin gene, widely distributed in the central and peripheral nervous systems.
- Carcinogenicity Testing— Long-term animal studies (typically 2 years in rodents) assessing whether a compound causes cancer.
- Carcinoid Syndrome— A set of symptoms (flushing, diarrhoea, wheezing) caused by hormones secreted by neuroendocrine tumours, particularly serotonin.
- Cardiolipin— A unique phospholipid found almost exclusively in the inner mitochondrial membrane, essential for the proper structure and function of the electron transport chain.
- Cardiotoxicity— Drug-induced damage to the heart muscle or cardiac conduction system.
- Cardiovascular Outcomes Trial (CVOT)— A large clinical trial specifically designed to evaluate a drug's effect on cardiovascular events such as heart attack, stroke, and cardiovascular death.
- Carrier Protein— A protein that binds to and transports other molecules through the bloodstream.
- Case Report— A detailed description of the diagnosis, treatment, and outcomes of an individual patient.
- Case Report (Publication)— A published scientific article describing the clinical history, treatment, and outcomes of an individual patient.
- Case Series— A collection of case reports describing similar clinical experiences in multiple patients.
- Case-Control Study— An observational study that compares individuals with a specific outcome (cases) to similar individuals without that outcome (controls) to identify factors associated with the outcome.
- Cathelicidin— A family of antimicrobial peptides found in humans and other mammals.
- Cell Membrane— The phospholipid bilayer that forms the boundary of all cells, controlling the passage of substances in and out.
- Cell-Penetrating Peptide— A short peptide (typically 5-30 amino acids) capable of crossing cell membranes and facilitating intracellular delivery of attached cargo.
- Cerebrospinal Fluid (CSF)— The clear fluid surrounding the brain and spinal cord that provides cushioning, nutrient delivery, and waste removal.
- Certificate of Analysis (COA)— A document reporting quality testing results for a specific batch of product, typically including purity (HPLC), identity (mass spectrometry), endotoxin levels, sterility, and other quality metrics.
- Chemokine— A subclass of cytokines that direct the migration of immune cells to sites of inflammation or infection.
- CHMP (Committee for Medicinal Products for Human Use)— The EMA's scientific committee responsible for evaluating human medicines and issuing opinions on marketing authorisation applications.
- Cholecystokinin (CCK)— A peptide hormone produced by intestinal I-cells after eating that stimulates gallbladder contraction, pancreatic enzyme secretion, and satiety.
- Chondrocyte— The only cell type found in healthy cartilage, responsible for producing and maintaining the cartilage matrix.
- Chronic Constipation— Persistent difficulty with bowel movements lasting at least 3 months.
- Chronic Inflammation— Prolonged inflammatory activity lasting weeks to years that can damage tissues and contribute to diseases including atherosclerosis, diabetes, cancer, and autoimmune conditions.
- Chronic Kidney Disease— Progressive loss of kidney function over months to years.
- Clearance (Pharmacology)— The volume of blood from which a drug is completely removed per unit of time, reflecting the body's efficiency at eliminating the drug.
- Clinical Endpoint— A direct measure of how a patient feels, functions, or survives — such as survival, heart attack, or ability to walk a certain distance.
- Clinical Practice Guideline— A systematically developed recommendation for healthcare professionals on appropriate treatment for specific clinical conditions.
- Clinical Trial— A structured research study conducted in human participants to evaluate the safety, efficacy, and optimal dosing of a medical intervention.
- ClinicalTrials.gov— The world's largest database of clinical studies, maintained by the US National Library of Medicine, containing records for trials conducted in over 200 countries.
- Clostridioides difficile Infection— A bacterial infection of the colon that causes severe diarrhoea, colitis, and potentially life-threatening complications.
- Cochrane Review— A systematic review published by the Cochrane Collaboration, widely considered the gold standard for evidence-based healthcare decision-making.
- Cognitive Decline— A gradual deterioration in memory, attention, processing speed, and executive function.
- Cohort Study— An observational study that follows a defined group of participants over time to examine the relationship between a drug exposure and health outcomes.
- Cold Chain— A temperature-controlled supply chain maintaining products within a specified range (typically 2-8°C) from manufacture to use.
- Collagen— The most abundant protein in the human body, providing structural strength to skin, tendons, ligaments, bones, and connective tissues.
- Collagen Synthesis— The biological production of collagen, the body's most abundant structural protein.
- Complement C5— A protein in the complement cascade that, when cleaved, generates C5a (a potent inflammatory mediator) and C5b (which initiates the membrane attack complex).
- Complement System— A cascade of approximately 30 proteins in the innate immune system that destroys pathogens, promotes inflammation, and clears damaged cells.
- Complete Blood Count (CBC)— A routine blood test measuring red blood cells, white blood cells, and platelets.
- Complete Response Letter (CRL)— A communication from the FDA indicating that the review of an application is complete but the agency has identified issues that must be resolved before approval can be granted.
- Composite Endpoint— A clinical trial outcome that combines multiple individual events into a single measure.
- Compounding Pharmacy— A pharmacy that creates customised medications by mixing or altering ingredients to meet individual patient needs.
- Conditional Marketing Authorisation— An EU pathway allowing early approval with less complete data for medicines addressing unmet medical needs in serious conditions.
- Confidence Interval— A range of values within which the true treatment effect is likely to fall, typically calculated at the 95% level.
- Conflict of Interest (Research)— A situation where a researcher's financial or personal interests could potentially influence the design, conduct, or interpretation of a study.
- Consensus Statement— A formal agreement among a panel of experts on a particular clinical topic, typically produced when the evidence base is insufficient for a formal guideline.
- Container Closure Integrity— The ability of a pharmaceutical container and its closure system to maintain a sterile barrier against microbial contamination throughout the product's shelf life.
- Continuous Glucose Monitoring (CGM)— A technology using a small sensor placed under the skin to measure glucose levels continuously throughout the day.
- Continuous Infusion— The slow, steady administration of a drug intravenously over an extended period using a pump.
- Contraindication— A condition or circumstance that makes a particular drug inadvisable because the risk of harm outweighs the benefit.
- Controlled Substance— A drug whose manufacture, possession, and use are regulated due to potential for abuse or dependence.
- Copper Peptide (GHK-Cu)— A naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper that declines with age.
- Corticotroph— A cell type in the anterior pituitary gland that produces adrenocorticotropic hormone (ACTH).
- Corticotropin-Releasing Hormone (CRH)— A 41 amino acid peptide produced by the hypothalamus that stimulates ACTH release from the anterior pituitary, initiating the HPA axis stress response cascade.
- Cortisol— The primary glucocorticoid hormone produced by the adrenal cortex in response to ACTH stimulation.
- Cosmeceutical— A product positioned between cosmetics and pharmaceuticals, containing biologically active ingredients (such as peptides) intended to have therapeutic effects on the skin beyond simple cosmetic enhancement.
- Counterfeit Medicine— A pharmaceutical product that is deliberately and fraudulently mislabelled with respect to its identity, composition, or source.
- Crossover Study— A trial design where participants receive both the treatment and control at different times with a washout period between.
- CT Scan (Computed Tomography)— An imaging technique using X-rays to create detailed cross-sectional images of the body.
- Current Good Manufacturing Practice (cGMP)— The most up-to-date version of GMP requirements enforced by regulatory authorities.
- Cushing's Disease— A specific form of Cushing's syndrome caused by an ACTH-secreting pituitary tumour.
- Cushing's Syndrome— The clinical condition resulting from prolonged excess cortisol, regardless of cause (pituitary tumour, adrenal tumour, exogenous steroids, or ectopic ACTH).
- Cutaneous T-Cell Lymphoma— A group of lymphomas where malignant T cells primarily affect the skin.
- CXCR4 Receptor— A chemokine receptor found on stem cells, immune cells, and cancer cells.
- Cyclic AMP (cAMP)— A key intracellular second messenger molecule produced when G-protein coupled receptors activate the enzyme adenylyl cyclase.
- Cyclic Peptide— A peptide with a ring structure formed by a bond between two points in the chain.
- Cyclisation— The process of forming a ring structure within a peptide chain by creating a bond between two points in the molecule.
- Cytokine— A broad category of small signalling proteins released by immune cells that regulate inflammation, immunity, and cell communication.
- Cytokine Release Syndrome— A systemic inflammatory response triggered by rapid release of cytokines from immune cells, potentially causing fever, hypotension, and organ dysfunction.
- Cytoprotection— The protection of cells from harmful agents or conditions.
D
- D-Amino Acid— The mirror-image form of the standard L-amino acids found in human proteins.
- Data Exclusivity— A regulatory protection period during which generic or biosimilar applicants cannot rely on the originator's clinical data to support their own approval application.
- Data Safety Monitoring Board (DSMB)— An independent committee of experts that monitors patient safety and treatment efficacy during a clinical trial.
- Deep Vein Thrombosis— A blood clot forming in a deep vein, usually in the legs.
- Defensin— A class of small, cysteine-rich antimicrobial peptides produced naturally by humans as part of the innate immune system.
- Degradation Product— A molecular species resulting from chemical breakdown of the active pharmaceutical ingredient during manufacturing, storage, or use.
- Delayed Gastric Emptying— Abnormally slow movement of food from the stomach into the small intestine.
- Depot Injection— A long-acting injectable formulation that releases the peptide slowly from the injection site over weeks to months.
- Dermal Peptide— A peptide designed to act on skin cells for therapeutic or cosmetic purposes.
- Desensitisation— A reduction in receptor responsiveness following prolonged or repeated agonist exposure, even though the agonist remains bound to the receptor.
- DEXA Scan— Dual-energy X-ray absorptiometry — the gold standard imaging technique for measuring bone mineral density.
- Diabetes Insipidus— A condition causing production of large volumes of dilute urine and excessive thirst due to insufficient vasopressin (central DI) or kidney resistance to vasopressin (nephrogenic DI).
- Diabetic Ketoacidosis— A serious complication of diabetes involving dangerously high blood sugar, dehydration, and accumulation of ketone bodies (acids) in the blood.
- Dipeptidyl Peptidase-4 (DPP-4)— An enzyme that rapidly degrades the incretin hormones GLP-1 and GIP by cleaving two amino acids from their N-terminus, giving natural GLP-1 a half-life of only 1-2 minutes.
- Disulphide Bond— A covalent bond formed between the sulphur atoms of two cysteine amino acid residues within a peptide or protein.
- DOI (Digital Object Identifier)— A unique, permanent identifier assigned to published scientific papers and other digital content.
- Dose Escalation Study— A clinical trial testing successively higher doses in small groups to determine the maximum tolerated dose.
- Dose Titration— The practice of gradually increasing a drug's dose over time to reach the optimal therapeutic level while minimising side effects.
- Dose-Dependent Toxicity— Adverse effects that increase in frequency or severity as the drug dose increases, reflecting a predictable relationship between drug exposure and toxicity.
- Dose-Limiting Toxicity— An adverse effect severe enough to prevent further dose increases in a dose escalation study.
- Dose-Ranging Study— A Phase II clinical trial that tests multiple dose levels simultaneously to identify the optimal dose for Phase III trials.
- Dose-Response Relationship— The correlation between the amount of drug administered and the magnitude of the resulting biological effect.
- Double-Blind Study— A clinical trial where neither participants nor researchers know who receives active treatment versus placebo.
- Downregulation— A decrease in the number or sensitivity of receptors on a cell surface in response to sustained stimulation.
- Drug Allergy— An immune-mediated adverse reaction to a medication, distinct from predictable pharmacological side effects.
- Drug Enforcement Administration (DEA)— The US federal agency responsible for enforcing controlled substance laws, classifying drugs into schedules, and investigating illegal manufacture and distribution.
- Drug Interaction— An alteration in one drug's effect caused by another drug, food, or substance.
- Drug Master File— A confidential document submitted to the FDA containing detailed manufacturing, processing, and quality information about a drug substance or component.
- Drug Recall— The removal of a pharmaceutical product from the market due to safety concerns, quality defects, or regulatory violations.
- Drug Shortage— A situation where supply of an approved drug is insufficient to meet demand, which can trigger regulatory provisions allowing compounding.
- Dual Agonist— A single molecule that activates two different receptor types simultaneously to produce complementary therapeutic effects.
- Dynorphin— A class of endogenous opioid peptides that preferentially bind to kappa opioid receptors.
- Dyslipidaemia— Abnormal blood lipid levels including elevated LDL cholesterol, triglycerides, or reduced HDL cholesterol.
E
- Echinocandin-Related Peptide— A class of lipopeptide antifungal drugs that inhibit beta-1,3-glucan synthase in fungal cell walls.
- Effectiveness— How well a drug works in real-world clinical practice, where patient populations are more diverse and adherence less controlled than in trials.
- Efficacy— The ability of a drug to produce a desired therapeutic effect under controlled clinical trial conditions.
- Efficacy (Pharmacology)— In pharmacological terms, the maximum biological response that a drug can produce regardless of dose.
- Elastin— A protein providing elasticity to skin, blood vessels, and lungs.
- Electron Transport Chain— A series of protein complexes in the inner mitochondrial membrane that transfer electrons through a series of redox reactions, generating the proton gradient that drives ATP synthesis.
- Electrospray Ionisation Mass Spectrometry (ESI-MS)— A mass spectrometry technique that ionises molecules from a liquid solution by applying high voltage.
- Elimination Half-Life— The time required for the body to eliminate half of the drug present in the systemic circulation.
- EMA (European Medicines Agency)— The EU agency responsible for scientific evaluation, supervision, and safety monitoring of medicines.
- Emergency Use Authorisation (EUA)— A mechanism allowing regulatory authorities to authorise unapproved medical products during public health emergencies based on a lower evidence threshold than full approval.
- Endocytosis— The cellular process of engulfing extracellular material by folding the cell membrane inward to form vesicles.
- Endogenous Peptide— A peptide that is naturally produced within the human body.
- Endometriosis— A condition where endometrial-like tissue grows outside the uterus, causing pain and infertility (affecting approximately 10% of reproductive-age women).
- Endopeptidase— A protease enzyme that cleaves peptide bonds within the interior of a peptide chain rather than at the ends.
- Endoplasmic Reticulum Stress— A cellular condition where the endoplasmic reticulum (the organelle responsible for protein folding and processing) becomes overwhelmed by misfolded proteins.
- Endorphin— A class of endogenous opioid peptides produced by the central nervous system and pituitary gland that reduce pain perception and produce feelings of wellbeing.
- Endotoxin Testing— Quality control testing for bacterial endotoxins (lipopolysaccharides) in injectable products.
- Energy Expenditure— The total calories burned through basal metabolism, physical activity, and the thermic effect of food.
- Enkephalin— A class of short endogenous opioid peptides (5 amino acids) found throughout the nervous system that modulate pain, mood, and stress responses.
- Enteric Coating— A polymer coating applied to oral drug formulations that resists dissolution in the acidic environment of the stomach but dissolves in the more alkaline small intestine.
- Epidermal Growth Factor (EGF)— A growth factor that stimulates the proliferation and differentiation of epithelial cells, promoting wound closure by stimulating skin cell migration and division.
- Equivalence Trial— A clinical trial designed to show that two treatments produce essentially the same effect, within pre-defined bounds.
- Erythropoietic Protoporphyria (EPP)— A rare genetic condition (approximately 1 in 75,000-200,000 people) caused by ferrochelatase enzyme deficiency, leading to protoporphyrin accumulation and extreme light sensitivity with painful phototoxic reactions.
- EudraCT Number— A unique identification number assigned to clinical trials conducted in the European Economic Area, used in the EU Clinical Trials Register.
- EudraVigilance (EU)— The European system for managing and analysing information on suspected adverse reactions to medicines authorised in the European Economic Area.
- Eumelanin— The brown-black form of melanin that provides effective photoprotection by absorbing UV radiation.
- European Pharmacopoeia (Ph. Eur.)— The pharmacopoeia that sets quality standards for medicines in Europe, published by the European Directorate for the Quality of Medicines.
- Evidence Hierarchy— A ranking system for the strength of different types of clinical evidence, from weakest to strongest: expert opinion, case reports, cohort studies, randomised controlled trials, systematic reviews and meta-analyses.
- Ex Vivo— Experiments performed on living cells, tissues, or organs removed from an organism but maintained in conditions mimicking the living environment.
- Excipient— An inactive ingredient in a pharmaceutical formulation that serves purposes such as stabilising the peptide, adjusting pH, controlling tonicity, or preserving the product.
- Exclusion Criteria— Characteristics that disqualify potential participants from a clinical trial, designed to protect patient safety and reduce confounding variables.
- Exocytosis— The cellular process of releasing molecules from a cell by fusing intracellular vesicles with the cell membrane.
- Exogenous Peptide— A peptide that originates from outside the body, whether administered as a therapeutic drug, consumed in food, or encountered in the environment.
- Exopeptidase— A protease enzyme that removes amino acids sequentially from either end of a peptide chain — aminopeptidases from the N-terminus and carboxypeptidases from the C-terminus.
- Extracellular Matrix (ECM)— The complex network of proteins and carbohydrates outside cells that provides structural support, regulates cell behaviour, and stores growth factors.
F
- Fast Track Designation— An FDA programme expediting development of drugs for serious conditions with unmet medical need.
- Fasting Plasma Glucose— A blood glucose measurement taken after at least 8 hours of fasting.
- FDA (Food and Drug Administration)— The United States federal agency responsible for regulating drugs, biological products, medical devices, and food safety.
- Fibroblast— The most common cell type in connective tissue, responsible for producing the extracellular matrix including collagen, elastin, and fibronectin.
- Fibroblast Growth Factor (FGF)— A family of growth factors that stimulate fibroblast proliferation, angiogenesis, and tissue development.
- Fibrodysplasia Ossificans Progressiva (FOP)— An extremely rare genetic condition (approximately 1 in 2 million) where soft tissues progressively turn into bone.
- First-Pass Metabolism— The phenomenon where a drug administered orally is partially metabolised in the gut wall and liver before reaching the systemic circulation, reducing its bioavailability.
- Flare Effect (GnRH Agonists)— The initial stimulatory surge in sex hormones (testosterone or oestrogen) that occurs during the first 1-2 weeks of GnRH agonist therapy, before receptor downregulation produces the intended suppression.
- Fmoc Chemistry— The most widely used chemical strategy for solid-phase peptide synthesis, using fluorenylmethyloxycarbonyl (Fmoc) as a temporary protecting group for amino groups.
- Follicle-Stimulating Hormone (FSH)— A gonadotropin hormone produced by the anterior pituitary that stimulates follicle development in women and sperm production in men.
- Formulation— The specific composition and preparation of a pharmaceutical product including active ingredient, excipients, and physical form.
- Fusion Peptide— A synthetic molecule combining two or more peptide sequences to create a single compound with multiple biological activities or enhanced properties.
G
- G-Protein Coupled Receptor (GPCR)— A large family of cell surface receptors with seven transmembrane domains that transmit signals through intracellular G-proteins.
- Gallium-68 DOTATATE PET— A highly sensitive PET imaging technique using gallium-68 labelled DOTATATE (a somatostatin analogue) to detect somatostatin receptor-positive tumours.
- Gastric Emptying— The process by which food moves from the stomach into the small intestine.
- Gastric Inhibitory Polypeptide (GIP)— A 42 amino acid incretin hormone produced by intestinal K-cells that stimulates insulin secretion and influences fat metabolism.
- Gastroparesis— Delayed gastric emptying causing nausea, vomiting, and abdominal discomfort.
- Generalised Myasthenia Gravis— The form of myasthenia gravis where muscle weakness extends beyond the eyes to affect limb, respiratory, and bulbar muscles.
- Genotoxicity— The potential of a substance to damage DNA, which could lead to mutations and potentially cancer.
- Gestational Diabetes— Diabetes developing during pregnancy in women without pre-existing diabetes.
- GH Stimulation Test— A diagnostic procedure to assess the pituitary gland's ability to produce growth hormone.
- Ghrelin— A 28 amino acid peptide produced primarily by the stomach that stimulates appetite and growth hormone release.
- GHRH Analogue— A synthetic compound that mimics natural growth hormone-releasing hormone, designed to stimulate the pituitary gland to produce growth hormone while resisting enzymatic degradation.
- Gigantism— Excessive growth occurring when a GH-secreting pituitary tumour develops before the growth plates close in childhood or adolescence, resulting in extreme height.
- GIP Receptor Agonist— A compound that activates the glucose-dependent insulinotropic polypeptide (GIP) receptor.
- Glial Cell-Derived Neurotrophic Factor (GDNF)— A neurotrophic factor that promotes survival of dopaminergic neurons and motor neurons.
- GLP-1 Receptor Agonist— A class of therapeutic compounds that activate the glucagon-like peptide-1 receptor, mimicking the effects of the natural hormone GLP-1.
- Glucagon— A 29 amino acid peptide hormone produced by pancreatic alpha cells that raises blood glucose by stimulating glycogenolysis and gluconeogenesis in the liver.
- Glucagon-Like Peptide (GLP-1)— A 30-31 amino acid hormone produced by intestinal L-cells after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
- Glucagon-Like Peptide-2 (GLP-2)— A 33 amino acid hormone co-secreted with GLP-1 from intestinal L-cells that promotes growth and function of the intestinal mucosa.
- Gluconeogenesis— The metabolic production of new glucose from non-carbohydrate sources (amino acids, lactate, glycerol) primarily in the liver.
- Glucose Tolerance Test— A diagnostic test for diabetes and impaired glucose tolerance where blood glucose is measured before and after drinking a glucose solution.
- Glycaemic Control— The management of blood glucose levels within acceptable ranges, assessed primarily through HbA1c.
- Glycogenolysis— The breakdown of glycogen (stored glucose) in the liver and muscles to release glucose into the bloodstream.
- Glycopeptide— A class of peptide antibiotics containing sugar groups, working by binding to bacterial cell wall precursors.
- Glycosylation— The attachment of sugar molecules (glycans) to a peptide or protein.
- GnRH Agonist— A synthetic peptide that activates the gonadotropin-releasing hormone receptor.
- GnRH Antagonist— A compound that blocks the GnRH receptor without activating it, causing immediate suppression of reproductive hormones without the initial flare seen with GnRH agonists.
- Gonadotroph— A cell type in the anterior pituitary gland that produces and secretes the gonadotropins LH and FSH in response to GnRH stimulation.
- Gonadotropin-Releasing Hormone (GnRH)— A 10 amino acid hypothalamic peptide controlling reproductive hormone release.
- Good Clinical Practice (GCP)— An international quality standard for the design, conduct, recording, and reporting of clinical trials.
- Good Manufacturing Practice (GMP)— A system of quality assurance standards ensuring pharmaceutical products are consistently produced according to established specifications.
- Granulation Tissue— The new connective tissue and blood vessels that form during the proliferative phase of wound healing.
- Growth Factor— A naturally occurring peptide or protein that stimulates cellular growth, proliferation, and differentiation.
- Growth Hormone (GH)— A 191 amino acid protein hormone secreted by the anterior pituitary gland that stimulates growth, cell reproduction, and tissue regeneration.
- Growth Hormone Deficiency— A condition where the pituitary gland produces insufficient growth hormone, causing growth failure in children and metabolic effects in adults.
- Growth Hormone Releasing Peptide (GHRP)— A class of short synthetic peptides (typically 6-7 amino acids) that stimulate growth hormone release by activating the ghrelin receptor.
- Growth Hormone Secretagogue— A compound that stimulates the secretion of growth hormone from the pituitary gland.
- Growth Hormone-Releasing Hormone (GHRH)— A 44 amino acid peptide hormone produced by the hypothalamus that stimulates growth hormone release from the anterior pituitary gland.
H
- Haemodialysis-Associated Pruritus— Severe itching experienced by patients undergoing haemodialysis for chronic kidney disease.
- Half-Life— The time required for the concentration of a drug in the body to decrease by half.
- Hazard Ratio— A measure of how quickly an event (such as death or disease progression) occurs in the treatment group compared to the control group.
- HbA1c (Glycated Haemoglobin)— A blood test reflecting average blood sugar over 2-3 months by measuring the percentage of haemoglobin with attached glucose.
- Health Canada— The Canadian federal department responsible for national health policy and drug regulation.
- Hepatotoxicity— Drug-induced liver injury, ranging from mild enzyme elevations to severe liver failure.
- Hereditary Angioedema (HAE)— A rare genetic condition causing recurrent severe swelling episodes in skin, GI tract, and airways due to excess bradykinin production.
- High-Performance Liquid Chromatography (HPLC)— The standard analytical technique for assessing peptide purity, separating components based on their interaction with a column material under high pressure.
- Histamine— A chemical mediator released from mast cells and basophils during allergic reactions, causing vasodilation, increased vascular permeability, itching, and smooth muscle contraction.
- HIV-Associated Lipodystrophy— Abnormal fat redistribution in HIV patients characterised by excess visceral fat and peripheral fat loss, increasing cardiometabolic risk.
- HPA Axis (Hypothalamic-Pituitary-Adrenal Axis)— The hormonal cascade linking the hypothalamus, pituitary, and adrenal glands that controls the stress response and cortisol production.
- HPG Axis (Hypothalamic-Pituitary-Gonadal Axis)— The hormonal system linking the hypothalamus, pituitary, and gonads that controls reproductive function and sex hormone production.
- Hyperinsulinaemia— Abnormally elevated insulin levels in the blood, typically occurring as a compensatory response to insulin resistance.
- Hypersensitivity Reaction— An exaggerated immune response to a drug ranging from mild skin reactions to severe systemic reactions.
- Hypoactive Sexual Desire Disorder (HSDD)— A condition characterised by persistently low sexual desire causing significant distress.
- Hypoglycaemia— Abnormally low blood sugar (generally below 70 mg/dL or 3.
- Hypothalamic-Pituitary Axis— The master hormonal regulatory system connecting the hypothalamus to the pituitary gland.
- Hypothalamus— A brain region that produces releasing and inhibiting hormones controlling pituitary function.
I
- Identity Testing— Analytical tests confirming that a pharmaceutical product contains the correct active ingredient.
- Idiosyncratic Reaction— An unpredictable adverse reaction to a drug that occurs in a small subset of patients, unrelated to the drug's known pharmacological effects or dose.
- IGF-Binding Protein (IGFBP)— A family of six proteins that bind to and regulate the activity of IGF-1 and IGF-2 in the bloodstream.
- Immunogenicity— The ability of a therapeutic peptide to provoke an unwanted immune response, potentially leading to formation of anti-drug antibodies that reduce effectiveness or cause allergic reactions.
- Immunomodulation— The adjustment of immune system activity — either enhancing underactive immunity or suppressing overactive immunity.
- Immunosuppressant— A drug that reduces immune system activity, used to prevent transplant rejection and treat autoimmune diseases.
- Impact Factor— A metric measuring the average number of citations received by articles in a journal over two years.
- Implant (Drug Delivery)— A device surgically placed under the skin to provide continuous, long-term peptide release.
- Import Restriction— Legal limitations on personal importation of pharmaceuticals from other countries.
- Impurity Profiling— The identification and quantification of all impurities present in a pharmaceutical product.
- In Silico— Research conducted using computer simulations and computational modelling rather than physical laboratory experiments.
- In Vitro— Experiments conducted outside a living organism in laboratory containers — test tubes, petri dishes, or cell culture plates.
- In Vitro Fertilisation (IVF)— An assisted reproduction technique where eggs are fertilised with sperm in a laboratory, and resulting embryos are transferred to the uterus.
- In Vivo— Experiments conducted in living organisms, encompassing both animal studies and human clinical trials.
- Inclusion Criteria— The specific characteristics that participants must have to be eligible for a clinical trial, such as age range, diagnosis, disease severity, and prior treatment history.
- Incretin— A class of gut hormones released after eating that stimulate insulin secretion in a glucose-dependent manner.
- Incretin Effect— The observation that oral glucose produces a greater insulin response than the same amount of glucose given intravenously.
- Indication— A specific disease or condition for which a drug has been approved by regulatory authorities.
- Infertility— The inability to conceive after 12 months of unprotected intercourse.
- Inflammation— The body's protective response to injury, infection, or irritation, characterised by redness, swelling, heat, pain, and loss of function.
- Inflammatory Phase (Wound Healing)— The initial response to tissue injury (lasting approximately 1-5 days) where immune cells remove debris and pathogens.
- Informed Consent— The process by which a clinical trial participant is fully informed about the study and voluntarily agrees to participate.
- Informed Prescribing— The practice of prescribing medications based on a thorough understanding of the drug's benefits, risks, alternatives, and the individual patient's circumstances.
- Infusion Reaction— An adverse reaction occurring during or shortly after intravenous drug infusion, ranging from mild flushing and fever to severe anaphylaxis.
- Injection Site Reaction— An adverse effect at the location of drug injection, including redness, swelling, pain, itching, or tissue hardening.
- Injection Site Rotation— The practice of systematically changing the location of subcutaneous or intramuscular injections to prevent local tissue damage, lipodystrophy, or reduced absorption.
- Innate Immunity— The body's first line of defence against pathogens, comprising physical barriers, antimicrobial peptides, complement proteins, and immune cells that respond rapidly and non-specifically.
- Institutional Review Board (IRB)— An independent committee that reviews clinical research protocols to ensure the protection of human participants.
- Insulin— A 51 amino acid peptide hormone produced by pancreatic beta cells that enables cells to take up glucose from the blood, lowering blood sugar levels.
- Insulin Resistance— A metabolic condition where cells respond poorly to insulin, requiring higher hormone levels to maintain normal glucose.
- Insulin Sensitivity— The degree to which cells respond to insulin signalling, the inverse of insulin resistance.
- Insulin Tolerance Test— A diagnostic test for growth hormone and cortisol deficiency where insulin is injected to induce hypoglycaemia, then GH and cortisol responses are measured.
- Insulin-Like Growth Factor 1 (IGF-1)— A hormone structurally similar to insulin that mediates many of growth hormone's effects in the body.
- Intention-to-Treat Analysis— A statistical method that analyses all participants based on their original group assignment, regardless of whether they completed treatment.
- Interchangeability (Biosimilars)— A regulatory determination that a biosimilar can be substituted for the reference product at the pharmacy level without prescriber intervention.
- Interferon— A family of signalling proteins released by cells in response to viral infection, activating antiviral defences in neighbouring cells.
- Interim Analysis— A pre-planned analysis of clinical trial data conducted before the study is complete.
- Interleukin— A large family of cytokines (IL-1 through IL-40+) that mediate communication between immune cells.
- International Council for Harmonisation (ICH)— An organisation that brings together regulatory authorities and pharmaceutical industry from Europe, Japan, and the US to develop harmonised guidelines for drug development and registration.
- Intramuscular Injection— A method of drug administration where the compound is injected directly into a muscle.
- Intraperitoneal Injection— Injection into the peritoneal cavity (the abdominal space containing the intestines and other organs).
- Intrathecal Administration— Drug delivery directly into the cerebrospinal fluid via injection into the spinal canal.
- Intravenous Administration— Drug delivery directly into a vein, providing immediate and complete bioavailability.
- Intrinsic Activity— The maximum response a drug can produce relative to a reference full agonist at the same receptor.
- Intrinsic Ageing— The natural, genetically determined ageing process of the skin characterised by gradual decline in collagen and elastin production, thinning of the epidermis, and reduced cell turnover.
- Inverse Agonist— A molecule that binds to a receptor and produces an effect opposite to that of an agonist, reducing the receptor's baseline constitutive activity below normal levels.
- Investigational Compound— A compound being evaluated in formal clinical trials under regulatory oversight but not yet approved.
- Investigational New Drug (IND)— A regulatory designation allowing a new compound to be tested in human clinical trials.
- Irritable Bowel Syndrome (IBS)— A functional gastrointestinal disorder characterised by abdominal pain and altered bowel habits.
- Isoform— A slightly different version of a peptide or protein that arises from variations in gene expression, alternative splicing, or post-translational modification.
K
- Kappa Opioid Receptor— One of the three main opioid receptor subtypes, found primarily in the spinal cord, brain, and peripheral tissues.
- Keratinocyte— The predominant cell type in the epidermis, responsible for producing keratin and forming the skin's protective barrier.
- Knockout Mouse Model— A genetically engineered mouse in which a specific gene has been inactivated (knocked out) to study the gene's function.
L
- Label Update— A revision to a drug's approved prescribing information or SmPC, typically to add new safety warnings, updated adverse event data, new indications, or modified dosing recommendations.
- Lactation Safety— Assessment of whether a drug is safe to use during breastfeeding, considering transfer into breast milk and potential effects on the nursing infant.
- LAL Test (Limulus Amebocyte Lysate)— The standard test for detecting bacterial endotoxins in pharmaceutical products, using a reagent derived from horseshoe crab blood cells.
- Lantipeptide (Lantibiotic)— A class of antimicrobial peptides containing unusual amino acids formed through post-translational modification, including lanthionine bridges.
- Lean Body Mass— Total body weight minus fat mass, comprising muscle, bone, organs, and water.
- Leukotriene— A class of inflammatory lipid mediators derived from arachidonic acid that promote bronchoconstriction, vascular permeability, and immune cell recruitment.
- Level of Evidence— A classification of the quality and reliability of clinical evidence supporting a treatment recommendation.
- Ligament Healing— The repair process for damaged ligament tissue, similar to but distinct from tendon healing.
- Linear Peptide— A peptide with two free ends (N-terminus and C-terminus) and no ring-forming bonds.
- Lipase— A pancreatic enzyme that breaks down fats.
- Lipid Panel— A blood test measuring total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
- Lipidation— The attachment of a fatty acid chain to a peptide molecule, typically to enable albumin binding and thereby extend the peptide's half-life in circulation.
- Lipodystrophy— A group of conditions characterised by abnormal body fat distribution or loss.
- Lipogenesis— The metabolic process of synthesising fatty acids and triglycerides for fat storage.
- Lipoglycopeptide— A glycopeptide antibiotic with an added lipophilic (fat-soluble) side chain that provides additional mechanisms of action, enhanced potency, and longer half-lives.
- Lipolysis— The metabolic breakdown of stored fat (triglycerides) into free fatty acids and glycerol for use as energy.
- Lipopeptide— A peptide covalently linked to a fatty acid.
- Liquid-Phase Peptide Synthesis— A peptide manufacturing method where synthesis occurs in solution rather than on a solid support.
- Liver Function Tests— A panel of blood tests assessing liver health including ALT, AST, alkaline phosphatase, bilirubin, and albumin.
- Loading Dose— An initial higher dose of a drug given to rapidly achieve therapeutic blood levels, followed by lower maintenance doses.
- Long-Term Potentiation (LTP)— A persistent strengthening of synaptic connections following repeated stimulation, considered the cellular mechanism underlying learning and memory.
- Luteinising Hormone (LH)— A gonadotropin hormone produced by the anterior pituitary that triggers ovulation in women and stimulates testosterone production in men.
- Lyophilisation (Freeze-Drying)— A preservation process removing water from a frozen peptide solution under vacuum.
- Lyoprotectant— An excipient added to a formulation before lyophilisation to protect the peptide from damage during the freeze-drying process.
M
- Maintenance Dose— The regular dose of a drug administered after initial loading or titration to maintain steady therapeutic blood levels.
- MALDI-TOF Mass Spectrometry— Matrix-assisted laser desorption/ionisation time-of-flight — a mass spectrometry technique particularly suited to peptide and protein analysis.
- Mantle Cell Lymphoma— A type of non-Hodgkin lymphoma arising from B cells in the mantle zone of lymph nodes.
- Market Exclusivity— A period during which no competing generic or biosimilar product can be approved for the same indication, regardless of patent status.
- Marketing Authorisation— Official permission granted by a regulatory authority allowing a drug to be marketed and sold within its jurisdiction.
- Mass Spectrometry— An analytical technique measuring molecular mass-to-charge ratios to identify and characterise peptides.
- Mast Cell— An immune cell found in tissues throughout the body that releases histamine, heparin, and other mediators during allergic and inflammatory reactions.
- Matrikine— A peptide fragment released during extracellular matrix degradation that acts as a signalling molecule, stimulating cells to produce new matrix components.
- Matrix Metalloproteinase (MMP)— A family of zinc-dependent enzymes that degrade extracellular matrix components.
- Maximum Tolerated Dose (MTD)— The highest dose that can be administered without causing unacceptable toxicity, typically established in Phase I dose escalation trials.
- Mechanism of Action— The specific biochemical process through which a drug produces its therapeutic effect, typically involving binding to a receptor, enzyme, or other biological target.
- MEDLINE— The National Library of Medicine's premier bibliographic database of biomedical journal articles, indexed with Medical Subject Headings (MeSH) terms.
- Medullary Thyroid Carcinoma (MTC)— A rare thyroid cancer arising from C-cells that produce calcitonin.
- MedWatch (FDA)— The FDA's safety information and adverse event reporting programme.
- Melanocortin Receptor— A family of five G-protein coupled receptors (MC1R through MC5R) that regulate skin pigmentation, appetite, sexual function, inflammation, and adrenal steroid production.
- Melanocyte— A specialised cell in the skin that produces melanin, the pigment responsible for skin colour and UV protection.
- Melanogenesis— The biological process by which melanocytes produce melanin pigment.
- Membrane Attack Complex (MAC)— A multi-protein pore formed by complement proteins C5b through C9 that creates holes in target cell membranes, causing cell death.
- Mesenchymal Stem Cell— A type of adult stem cell found in bone marrow, fat tissue, and other sources that can differentiate into bone, cartilage, muscle, and fat cells.
- Meta-Analysis— A statistical technique combining results from multiple independent studies to produce a more precise estimate of treatment effect.
- Metabolic Syndrome— A cluster of interconnected conditions — central obesity, insulin resistance, elevated blood pressure, high triglycerides, and low HDL cholesterol — that together significantly increase cardiovascular risk.
- MHRA (Medicines and Healthcare products Regulatory Agency)— The UK regulatory body responsible for ensuring the safety, quality, and efficacy of medicines and medical devices.
- Microneedle Patch— A drug delivery device containing arrays of microscopic needles (typically 25-2000 micrometres long) that painlessly penetrate the outer skin layer to deliver drugs directly to the dermis or epidermis.
- Microsphere Formulation— A drug delivery system where the peptide is encapsulated in tiny biodegradable polymer spheres (typically 10-100 micrometres) that gradually degrade at the injection site, releasing the drug at a controlled rate.
- Misuse of Drugs Act (UK)— The primary UK legislation controlling dangerous and harmful drugs, classifying them into Classes A, B, and C based on harm potential.
- Mitochondria— Organelles within cells responsible for generating the majority of cellular energy in the form of ATP through oxidative phosphorylation.
- Mitochondrial Dysfunction— Impaired mitochondrial function leading to inadequate cellular energy production and increased oxidative stress.
- Mitochondrial Membrane— The double membrane system surrounding mitochondria — the outer membrane is permeable to small molecules while the inner membrane is highly selective and contains the electron transport chain.
- Molecular Weight— The total mass of a molecule, calculated by summing the atomic weights of all its constituent atoms.
- Morbid Obesity (Class III)— The most severe category of obesity, defined as BMI ≥40 or BMI ≥35 with serious weight-related comorbidities.
- MRI (Magnetic Resonance Imaging)— An imaging technique using magnetic fields and radio waves to produce detailed images of soft tissues.
- MRSA (Methicillin-Resistant Staphylococcus aureus)— A strain of Staphylococcus aureus resistant to methicillin and most beta-lactam antibiotics.
- Mu Opioid Receptor— The primary opioid receptor subtype responsible for the analgesic, euphoric, and respiratory depressant effects of traditional opioid drugs.
- Multiple Myeloma— A cancer of plasma cells in bone marrow, the second most common blood cancer.
- Multiple Sclerosis— An autoimmune disease where the immune system attacks the myelin sheath surrounding nerve fibres in the brain and spinal cord, causing neurological symptoms.
- Myasthenia Gravis— An autoimmune neuromuscular disorder where antibodies attack acetylcholine receptors at the neuromuscular junction, causing fluctuating muscle weakness.
- Myelination— The process of forming a myelin sheath — a fatty insulating layer — around nerve fibres, which dramatically increases signal transmission speed.
- Myofibroblast— A specialised cell with properties of both fibroblasts and smooth muscle cells that plays a crucial role in wound contraction during tissue repair.
N
- N-Terminus— The end of a peptide or protein chain that has a free amino group (-NH2).
- Narrative Review— A literature review that summarises and interprets research on a topic without the structured, reproducible methodology of a systematic review.
- Nasal Administration— Drug delivery via the nasal mucosa, enabling peptide absorption into the systemic circulation while avoiding gastrointestinal degradation.
- Natriuretic Peptide— A family of peptide hormones (ANP, BNP, CNP) that regulate blood pressure and fluid balance by promoting sodium excretion and vasodilation.
- Nausea (Drug-Related)— A common side effect reported by 15-44% of patients initiating GLP-1 receptor agonist therapy.
- NCT Number— A unique identification code assigned to every clinical trial registered on ClinicalTrials.
- Needle Gauge— A measurement of needle diameter — higher gauge numbers indicate thinner needles.
- Negative Feedback Loop— A self-regulating biological mechanism where the output of a hormonal system inhibits its own production, maintaining homeostasis.
- Nephrogenic Diabetes Insipidus— A form of diabetes insipidus where the kidneys fail to respond to vasopressin despite adequate hormone levels.
- Nephrotoxicity— Drug-induced kidney damage.
- Nerve Growth Factor (NGF)— The first discovered neurotrophic factor (Nobel Prize 1986), essential for survival and maintenance of sensory and sympathetic neurons.
- Network Meta-Analysis— A statistical method that compares multiple treatments simultaneously by combining direct evidence (from head-to-head trials) with indirect evidence (from trials sharing a common comparator).
- Neurodegeneration— The progressive loss of structure or function of neurons, leading to conditions such as Alzheimer's disease, Parkinson's disease, and ALS.
- Neuroendocrine Tumour (NET)— A tumour arising from neuroendocrine cells, most commonly in the GI tract and pancreas.
- Neuroinflammation— Inflammation within the central nervous system, involving activation of microglia and astrocytes.
- Neuromuscular Junction— The synapse between a motor neuron and a muscle fibre where acetylcholine transmits the signal for muscle contraction.
- Neuropeptide— A peptide that acts as a signalling molecule in the nervous system, functioning as a neurotransmitter or neuromodulator.
- Neuropeptide Y (NPY)— A 36 amino acid neuropeptide that is one of the most abundant peptides in the brain.
- Neuroplasticity— The brain's ability to reorganise its structure and connections throughout life, underlying learning, memory, and recovery from injury.
- Neuroregeneration— The regrowth or repair of nervous tissue.
- Neurotoxicity— Drug-induced damage to the nervous system, potentially affecting the brain, spinal cord, or peripheral nerves.
- Neurotransmitter— A chemical messenger released at synapses to transmit signals between neurons.
- Neurotrophic Factor— A class of proteins supporting neuronal survival, growth, and function.
- Neutralising Antibody— An anti-drug antibody that binds to the active site of a therapeutic peptide, directly preventing it from interacting with its biological target.
- Neutropenia— An abnormally low count of neutrophils (a type of white blood cell), increasing susceptibility to infection.
- New Drug Application (NDA)— A formal submission to the US FDA containing all preclinical, clinical, manufacturing, and labelling data needed to demonstrate a new drug is safe and effective.
- Nitric Oxide (NO)— A small signalling molecule produced by nitric oxide synthase enzymes that plays critical roles in vasodilation, immune defence, neurotransmission, and tissue repair.
- No Observed Adverse Effect Level (NOAEL)— The highest dose of a compound at which no adverse effects are observed in preclinical toxicology studies.
- Nociception— The sensory process by which the nervous system detects and transmits pain signals from potentially damaging stimuli.
- Nocturnal Enuresis (Bedwetting)— Involuntary urination during sleep, affecting children and some adults.
- Non-Alcoholic Steatohepatitis (NASH)— A form of liver disease characterised by fat accumulation, inflammation, and liver cell damage not caused by alcohol.
- Non-Inferiority Trial— A clinical trial designed to show that a new treatment is not meaningfully worse than an existing treatment by more than a pre-specified margin.
- Nootropic— A substance claimed to improve cognitive function including memory, attention, and motivation.
- Novel Food Regulation— EU and UK regulatory framework governing foods without significant consumption history before May 1997.
- NT-proBNP— N-terminal pro-brain natriuretic peptide — an inactive fragment released alongside BNP from cardiac ventricles under stress.
- Number Needed to Treat (NNT)— The number of patients who need to be treated with a drug for one additional patient to benefit compared to the control group.
O
- Obesity— A chronic disease characterised by excessive body fat accumulation (BMI ≥30) that increases health risks.
- Observational Study— A research study where outcomes are recorded without intervening to assign treatments.
- Oestrogen— The primary female sex hormones (estradiol, estrone, estriol) produced by the ovaries under FSH and LH stimulation.
- Off-Label Use— Prescribing an approved drug for a condition, population, or dosage not included in its approved labelling.
- Open-Label Extension Study— A follow-on study where participants who completed a blinded trial continue receiving the active treatment in an unblinded setting, typically for months or years.
- Open-Label Study— A clinical trial where both participants and researchers know which treatment is being given.
- Opioid Receptor— A group of G-protein coupled receptors found throughout the nervous system that mediate pain perception, mood, and reward.
- Oral Peptide Delivery— The administration of peptide drugs by mouth, extremely challenging because digestive enzymes and poor intestinal absorption destroy most of the compound.
- Orphan Drug Designation— A special regulatory status for drugs treating rare diseases (fewer than 200,000 US patients or fewer than 5 in 10,000 EU).
- Osteoblast— A bone-forming cell responsible for producing and mineralising new bone matrix.
- Osteoclast— A large cell responsible for breaking down and resorbing bone tissue.
- Osteopenia— Bone density lower than normal but not low enough to be classified as osteoporosis (T-score between -1.
- Osteoporosis— Decreased bone density and deterioration of bone structure leading to increased fracture risk.
- Over-the-Counter (OTC)— A medication available without a prescription, considered safe for self-medication when used as directed.
- Oxidative Phosphorylation— The metabolic pathway in mitochondria where ATP is generated using energy from electron transport chain reactions.
- Oxidative Stress— An imbalance between the production of reactive oxygen species (free radicals) and the body's ability to neutralise them, leading to cellular damage.
- Oxytocin System— The hormonal system centred on oxytocin, a 9 amino acid peptide involved in labour, lactation, and social bonding.
P
- P-Value— The probability that an observed difference between groups in a clinical trial would occur if there were truly no difference.
- Paget's Disease of Bone— A chronic bone disorder where normal bone turnover is accelerated and disorganised, leading to enlarged, weakened bones prone to deformity and fracture.
- Pancreatitis— Inflammation of the pancreas causing severe abdominal pain, elevated pancreatic enzymes, and potential complications.
- Parathyroid Hormone (PTH)— An 84 amino acid peptide hormone produced by the parathyroid glands that raises blood calcium levels by stimulating bone resorption and kidney calcium reabsorption.
- Parathyroid Hormone (PTH) Analogue— A synthetic compound mimicking PTH's ability to stimulate bone formation when given in intermittent pulses.
- Partial Agonist— A molecule that binds to and activates a receptor but produces only a partial response compared to a full agonist, even at full receptor occupancy.
- Particulate Matter Testing— Testing for visible and sub-visible particles in injectable pharmaceutical products.
- Patent Exclusivity— Legal protection giving a pharmaceutical company exclusive rights to manufacture and sell a drug for a defined period.
- Patient Information Leaflet (PIL)— A document written in accessible language included with every medicine that informs patients about the drug's purpose, proper use, side effects, storage, and other essential information.
- Patient-Reported Outcome (PRO)— A health outcome directly reported by the patient without interpretation by a clinician.
- Peak Plasma Concentration (Cmax)— The highest concentration of a drug achieved in the blood after administration, before elimination begins to reduce levels.
- Peer-Reviewed Publication— A scientific article evaluated by independent experts before journal acceptance.
- PEGylation— The process of attaching polyethylene glycol (PEG) polymer chains to a peptide or protein to extend its half-life in the body.
- Pen Injector— A reusable or disposable injection device shaped like a pen that holds a multi-dose cartridge and allows the patient to dial their prescribed dose.
- Peptidase— A type of protease enzyme that specifically cleaves peptide bonds.
- Peptide— A short chain of amino acids linked by peptide bonds, typically containing between 2 and 50 residues.
- Peptide Bond— A covalent chemical bond formed between the carboxyl group of one amino acid and the amino group of another, releasing a molecule of water.
- Peptide Conjugate— A peptide chemically linked to another molecule — such as a toxin, fluorescent label, PEG chain, or fatty acid — to modify its properties.
- Peptide Folding— The process by which a linear chain of amino acids adopts its functional three-dimensional conformation.
- Peptide Library— A large collection of peptides with systematically varied sequences, used in drug discovery to screen for compounds that bind to a specific biological target.
- Peptide Mapping— An analytical technique where a peptide or protein is enzymatically digested into smaller fragments that are separated and identified by HPLC and mass spectrometry.
- Peptide Purity— The percentage of a sample consisting of the intended target peptide.
- Peptide Sequence Homology— The degree of similarity between the amino acid sequences of two or more peptides, expressed as a percentage of identical or similar residues.
- Peptide Vaccine— A vaccine using synthetic peptide fragments (epitopes) to stimulate an immune response against specific disease targets.
- Peptide YY (PYY)— A 36 amino acid gut hormone released from intestinal L-cells after eating that suppresses appetite and slows gastric emptying.
- Peptidomimetic— A synthetic compound designed to mimic the biological activity of a natural peptide while having a modified chemical structure that may improve stability, bioavailability, or resistance to enzymatic degradation.
- Per-Protocol Analysis— A statistical method that includes only participants who completed the trial as prescribed, excluding dropouts and non-adherent patients.
- Percentage Weight Loss— Weight reduction expressed as a percentage of starting body weight — the standard primary efficacy measure in obesity clinical trials.
- Personal Importation— The practice of an individual importing pharmaceutical products from another country for their own personal use.
- PET Scan (Positron Emission Tomography)— A nuclear medicine imaging technique that detects metabolic activity in the body using radioactive tracers.
- Phage Display— A laboratory technique in which peptide sequences are expressed on the surface of bacteriophage (virus) particles, allowing researchers to screen vast libraries of peptide variants for binding to a target of interest.
- Pharmacodynamics— The study of what a drug does to the body — its biological effects, mechanism of action, and the relationship between drug concentration and therapeutic response.
- Pharmacokinetics— The study of how the body processes a drug over time, encompassing absorption, distribution, metabolism, and excretion (ADME).
- Pharmacopoeia— An official reference publication containing standards for the identity, strength, quality, and purity of pharmaceutical substances and dosage forms.
- Pharmacovigilance— The science of detecting, assessing, and preventing adverse drug reactions throughout a drug's commercial life.
- Phase I Clinical Trial— The first stage of human testing, primarily assessing safety, tolerability, pharmacokinetics, and appropriate dosing in 20-100 participants.
- Phase II Clinical Trial— The second stage of clinical testing, evaluating preliminary efficacy in 100-300 patients with the target condition while continuing to assess safety.
- Phase III Clinical Trial— The most extensive stage of clinical testing, definitively confirming efficacy and safety in 300-3,000+ patients through randomised controlled trials.
- Phase IV Clinical Trial— Studies conducted after regulatory approval to monitor long-term safety, detect rare adverse events, and evaluate real-world effectiveness in broader patient populations.
- Pheomelanin— The red-yellow form of melanin that provides less photoprotection than eumelanin and can generate free radicals under UV exposure.
- Photoageing— Premature skin ageing caused by cumulative UV radiation exposure, characterised by wrinkles, pigmentation changes, loss of elasticity, and rough texture.
- Photoprotection— Protection of skin from UV radiation damage, achieved through external means (sunscreen, clothing) or biological mechanisms (increased melanin).
- Pituitary Gland— A small endocrine gland at the base of the brain that produces and secretes several critical hormones including growth hormone, LH, FSH, ACTH, and TSH.
- Pivotal Trial— A Phase III clinical trial whose results form the primary basis for a regulatory approval application.
- Placebo-Controlled Study— A clinical trial where the control group receives an inactive substance identical in appearance to the active treatment.
- Platelet-Derived Growth Factor (PDGF)— A growth factor released from platelets during blood clotting that stimulates cell growth, migration, and wound healing.
- Platform Trial— A flexible trial design that evaluates multiple interventions simultaneously against a shared control group, with the ability to add or drop treatment arms over time.
- Polycystic Ovary Syndrome (PCOS)— A common endocrine disorder affecting up to 10% of women, characterised by hormonal imbalance, irregular periods, and ovarian cysts.
- Polymyxin— A class of cyclic lipopeptide antibiotics that disrupt gram-negative bacterial cell membranes.
- Polypeptide— A single chain of amino acids linked by peptide bonds, typically containing more than 20 residues.
- Post Hoc Analysis— A statistical analysis of clinical trial data that was not specified in the original protocol, conducted after the study results are known.
- Post-Marketing Commitment— A study that a drug sponsor agrees to conduct after approval, distinct from post-marketing requirements in that commitments are agreed upon rather than mandated.
- Post-Marketing Requirement— A study or clinical trial that the FDA requires a drug sponsor to conduct after approval to further assess safety, efficacy, or optimal use.
- Post-Translational Modification— A chemical change made to a peptide or protein after it has been synthesised, which can affect the molecule's stability, activity, or interactions.
- Posterior Pituitary— The rear lobe of the pituitary gland (neurohypophysis) that stores and releases oxytocin and vasopressin.
- Postpartum Haemorrhage— Excessive bleeding after childbirth, a leading cause of maternal mortality worldwide.
- Postprandial Glucose— Blood glucose measured after eating, typically at 1-2 hours after a meal.
- Potency— A measure of the amount of drug required to produce a given biological effect.
- Potency Assay— A test measuring the biological activity of a pharmaceutical product, expressed relative to a reference standard.
- Power Calculation (Sample Size)— A statistical calculation performed before a clinical trial begins to determine the minimum number of participants needed to reliably detect a meaningful treatment difference.
- Pre-Filled Syringe— A single-use syringe that comes pre-loaded with a specific dose of medication, ready for immediate administration.
- Preclinical Research— Scientific studies conducted before human testing, including laboratory experiments (in vitro), animal studies (in vivo), and computational modelling.
- Precocious Puberty— The onset of puberty before age 8 in girls or 9 in boys due to early HPG axis activation.
- Prediabetes— A metabolic state with blood glucose levels higher than normal but below the diabetes diagnostic threshold (HbA1c 5.
- Pregnancy Category— A classification system indicating the risk of using a drug during pregnancy based on available evidence.
- Preprint— A scientific manuscript shared publicly before formal peer review, typically on servers such as bioRxiv or medRxiv.
- Prescribing Information (PI)— The official FDA-approved document for healthcare professionals that contains comprehensive information about a drug including indications, dosing, contraindications, warnings, adverse reactions, and clinical pharmacology.
- Prescription-Only Medicine (POM)— A medication requiring a valid prescription from a licensed healthcare professional.
- Primary Endpoint— The main outcome measure in a clinical trial that the study is specifically designed and powered to evaluate.
- Priority Review— An FDA designation shortening the review timeline from 10-12 months to approximately 6-8 months for drugs offering significant improvements in safety or effectiveness for serious conditions.
- Process Validation— Documented evidence that a manufacturing process consistently produces a product meeting predetermined specifications and quality attributes.
- Product Liability— The legal responsibility of a manufacturer or seller for harm caused by a defective product.
- Progesterone— A steroid hormone produced by the ovaries that plays a key role in the menstrual cycle, pregnancy, and embryonic development.
- Prolactin— A protein hormone produced by the anterior pituitary that stimulates milk production in breastfeeding women.
- Proliferative Phase (Wound Healing)— The wound healing phase (days 3-21) where new tissue is actively formed.
- Proof-of-Concept Study— An early-phase clinical trial (typically Phase IIa) designed to determine whether a drug produces the expected biological effect in patients.
- Prostaglandin— A family of lipid signalling molecules derived from arachidonic acid that mediate inflammation, pain, fever, and many other physiological processes.
- Prostate Cancer— The most common non-skin cancer in men.
- Protease— An enzyme that cleaves peptide bonds, breaking down peptides and proteins into smaller fragments.
- Proteasome Inhibitor— A drug that blocks the proteasome — the cellular complex responsible for degrading damaged proteins.
- Protein— A large, complex molecule composed of one or more polypeptide chains folded into a specific three-dimensional structure.
- Protein Aggregation— The clumping together of misfolded proteins into insoluble aggregates.
- Proteolysis— The breakdown of peptides and proteins into smaller fragments or individual amino acids by enzymes called proteases.
- Protocol Amendment— A formal, approved modification to a clinical trial protocol made after the study has begun.
- Protocol Deviation— Any departure from the approved clinical trial protocol, whether intentional or accidental.
- Pruritus (Chronic Itch)— Persistent itching that significantly impacts quality of life.
- Publication Bias— The tendency for studies with positive or statistically significant results to be published more frequently than studies with negative or inconclusive results.
- PubMed— A free database of over 36 million biomedical literature citations maintained by the US National Library of Medicine.
- Pulmonary Embolism— A blood clot that travels to and blocks a pulmonary artery in the lungs, a potentially life-threatening emergency.
Q
- Quality Assurance— The systematic activities and procedures designed to ensure pharmaceutical products consistently meet quality requirements throughout the entire manufacturing process.
- Quality Control— The testing and inspection activities performed on pharmaceutical products to verify they meet established specifications before release.
- Quality of Life Endpoint— A clinical trial outcome measure that assesses the overall impact of a disease and its treatment on a patient's physical, mental, and social wellbeing.
R
- Radiopharmaceutical Peptide— A peptide conjugated to a radioactive isotope for imaging or therapy.
- Randomisation— The process of randomly assigning clinical trial participants to treatment or control groups, ensuring that any differences in outcomes are attributable to the treatment rather than pre-existing differences.
- Randomised Controlled Trial (RCT)— A study design where participants are randomly assigned to treatment or control groups, considered the gold standard for evaluating drug efficacy.
- Reactive Oxygen Species (ROS)— Chemically reactive molecules containing oxygen (including superoxide, hydrogen peroxide, and hydroxyl radicals) that can damage DNA, proteins, and cell membranes.
- Real-World Evidence— Clinical evidence generated from real-world data sources such as electronic health records, insurance claims, patient registries, and observational studies, as opposed to controlled clinical trials.
- Rebound Effect— An exaggerated return or worsening of symptoms when a drug is discontinued, often exceeding the original pre-treatment severity.
- Receptor Agonist— A molecule that binds to a specific receptor and activates it, triggering a biological response.
- Receptor Antagonist— A molecule that binds to a receptor without activating it, blocking the natural ligand from binding and preventing the receptor's biological response.
- Receptor Binding Affinity— A measure of how strongly a molecule binds to its target receptor, typically expressed as a dissociation constant (Kd).
- Receptor Internalisation— The process by which a cell takes receptor-ligand complexes from the surface into the cell interior.
- Recombinant Peptide— A peptide or protein produced using recombinant DNA technology, where the gene encoding the compound is inserted into a host organism such as bacteria or yeast.
- Reconstitution— Dissolving a lyophilised peptide powder in sterile liquid before administration.
- Reference Listed Drug— The originally approved drug product against which generics or biosimilars are compared for regulatory approval.
- Reference Standard— A highly characterised, pure substance used as a benchmark for analytical testing.
- Registration Trial— A clinical trial specifically designed to support a regulatory submission for drug approval.
- Regulatory Submission— A formal application package submitted to a regulatory authority (FDA, EMA, Health Canada, etc.
- Relative Risk Reduction— The percentage decrease in the risk of an event in the treatment group compared to the control group.
- Release Testing— The set of quality control tests performed on each batch of finished pharmaceutical product before it can be released for distribution and sale.
- Remodelling Phase (Wound Healing)— The final wound healing phase (weeks to years) where new tissue matures and strengthens.
- Renal Clearance— The rate at which the kidneys remove a drug from the blood through filtration and excretion in urine.
- Renal Function Tests— Blood tests assessing kidney function, primarily serum creatinine and estimated glomerular filtration rate (eGFR).
- Renin-Angiotensin-Aldosterone System (RAAS)— A hormonal cascade that regulates blood pressure, fluid balance, and electrolyte homeostasis through the peptide hormones angiotensin I and II and the steroid hormone aldosterone.
- Reproductive Toxicity— The potential of a drug to adversely affect fertility, embryo-foetal development, or postnatal development.
- Research Chemical— A compound sold for laboratory research purposes rather than human consumption, labelled 'not for human consumption' or 'research use only'.
- Research Compound— A compound with scientific research interest that has not entered or completed the clinical trial process required for regulatory approval.
- Research Ethics Committee (REC)— The UK and European equivalent of the US Institutional Review Board, responsible for reviewing and approving clinical research protocols to ensure ethical conduct and protection of human participants.
- Research Use Only (RUO)— A labelling designation indicating that a product is intended solely for laboratory research and is not approved for diagnostic, therapeutic, or human use.
- Residual Solvent Testing— Analysis detecting trace amounts of organic solvents remaining from the manufacturing process.
- Retraction— The formal withdrawal of a published paper due to errors, fabricated data, or other serious problems that undermine its reliability.
- Rett Syndrome— A rare neurodevelopmental disorder (approximately 1 in 10,000-15,000 female births) caused by MECP2 gene mutations, leading to regression of acquired skills, stereotypical hand movements, and severe impairment.
- Reversed-Phase HPLC— The most commonly used HPLC variant for peptide analysis, separating peptides based on hydrophobicity using a non-polar stationary phase and polar mobile phase.
- Risk Evaluation and Mitigation Strategy (REMS)— An FDA-required safety programme for drugs with known serious risks, ensuring benefits outweigh risks.
- Risk-Benefit Assessment— The systematic evaluation of a drug's potential benefits against its potential risks that forms the basis of all regulatory approval decisions.
- Rolling Submission— An FDA process allowing drug sponsors with Fast Track designation to submit completed sections of their application for review as they become available, rather than waiting until the entire package is complete.
- Run-In Period— A pre-treatment phase at the beginning of a clinical trial during which all participants may receive placebo or standardised care.
S
- Satiety— The feeling of fullness and satisfaction after eating that suppresses further food intake.
- Scar Tissue (Fibrosis)— Dense, fibrous tissue that replaces normal tissue after injury.
- Schedule (Drug Scheduling)— A classification system categorising controlled substances based on medical utility and abuse potential.
- Second Messenger— A small intracellular signalling molecule released inside a cell in response to receptor activation, which amplifies and propagates the signal from the cell surface.
- Secondary Endpoint— An additional outcome measure providing supporting evidence about a drug's effects beyond the primary endpoint.
- Secretagogue— A substance that stimulates secretion of a hormone or other molecule from a cell.
- Selectivity— The ability of a drug to preferentially bind to one receptor subtype or target over others.
- Sepsis— A life-threatening organ dysfunction caused by the body's dysregulated response to infection.
- Serious Adverse Event (SAE)— An adverse event that results in death, is life-threatening, requires hospitalisation, causes persistent disability, or results in a congenital anomaly.
- Serum IGF-1 Level— A blood test measuring insulin-like growth factor 1 concentration, the primary clinical marker for assessing growth hormone activity.
- Shelf Life— The period during which a pharmaceutical product remains within its approved quality specifications when stored under recommended conditions.
- Short Bowel Syndrome— A condition caused by surgical removal or disease of a large portion of the small intestine, leading to malabsorption requiring parenteral nutrition.
- Signal Peptide (Skincare)— A category of cosmetic peptides designed to stimulate fibroblasts to produce more collagen, elastin, or other structural proteins.
- Signal Transduction— The process by which a cell converts an extracellular signal — such as a peptide hormone binding to its receptor — into an intracellular response.
- Single-Blind Study— A clinical trial where participants do not know whether they are receiving active treatment or placebo, but the researchers do.
- Skin Barrier Function— The skin's ability to prevent water loss, resist environmental damage, and block entry of pathogens and irritants.
- Small Molecule Drug— A low molecular weight compound (typically under 900 daltons) that can often be taken orally and is manufactured through chemical synthesis.
- SNAC Technology— Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate — the specific absorption enhancer co-formulated with semaglutide in the oral tablet Rybelsus.
- Solid-Phase Peptide Synthesis (SPPS)— The standard method for chemically manufacturing peptides, building chains one amino acid at a time on a solid resin support.
- Somatostatin— A naturally occurring peptide hormone (14 or 28 amino acids) that broadly inhibits the release of growth hormone, insulin, glucagon, and multiple gastrointestinal hormones.
- Somatostatin Analogue— A synthetic peptide that mimics the inhibitory effects of natural somatostatin, suppressing the release of growth hormone, insulin, glucagon, and gastrointestinal peptides.
- Somatostatin Receptor Scintigraphy— A nuclear medicine imaging technique using radiolabelled somatostatin analogues to detect tumours that overexpress somatostatin receptors.
- Somatotroph— A growth hormone-producing cell in the anterior pituitary gland, comprising approximately 50% of pituitary cells.
- Stability Testing— Experiments determining how a peptide drug's quality changes over time under defined storage conditions.
- Stapled Peptide— A peptide stabilised by a synthetic chemical bridge (staple) across adjacent turns of its helical structure.
- Statistical Significance— A measure of how likely an observed result occurred by chance.
- Steady State— The condition reached during repeated drug dosing when the rate of drug administration equals the rate of drug elimination, resulting in a stable average drug concentration.
- Stem Cell— An undifferentiated cell capable of self-renewal and differentiation into specialised cell types.
- Stem Cell Mobilisation— The process of moving haematopoietic stem cells from bone marrow into the peripheral blood for collection and transplantation.
- Sterile Water for Injection— Purified water that has been sterilised and is free from preservatives, intended for single-use reconstitution of injectable medications.
- Sterility Testing— Quality control confirming the absence of viable microorganisms in injectable products.
- Stratification— The process of dividing clinical trial participants into subgroups (strata) based on characteristics such as age, sex, disease severity, or baseline BMI before randomisation.
- Stratum Corneum— The outermost layer of the skin, composed of dead keratinocytes (corneocytes) embedded in a lipid matrix.
- Subcutaneous Adipose Tissue— Fat stored beneath the skin, distributed across the body.
- Subcutaneous Injection— A method of drug administration where the compound is injected into the fatty tissue layer beneath the skin.
- Subgroup Analysis— An analysis examining treatment effects in specific patient subsets (e.
- Substance P— An 11 amino acid neuropeptide involved in pain signalling, inflammation, and mood regulation.
- Summary of Product Characteristics (SmPC)— The EU equivalent of the US prescribing information — a legally binding document approved as part of the marketing authorisation that provides healthcare professionals with all information needed to prescribe and monitor a medicine safely and effectively.
- Superiority Trial— A clinical trial designed to show that a new treatment is better than the comparator (placebo or active control) by a statistically significant margin.
- Supplemental New Drug Application (sNDA)— A submission to the FDA to modify an existing drug approval — for example, to add a new indication, change dosing, update safety information, or modify the formulation.
- Surrogate Endpoint— A laboratory measurement or physical sign used as a substitute for a direct clinical outcome when the true outcome would take too long to measure.
- Sustained Release Formulation— A drug product engineered to release the active compound slowly and continuously over an extended period.
- Synaptic Plasticity— The ability of synapses (connections between neurons) to strengthen or weaken over time based on activity.
- Synthetic Peptide— A peptide produced through chemical synthesis rather than biological expression, most commonly using solid-phase peptide synthesis.
- Systematic Review— A rigorous review of all available research on a specific question using pre-defined methods to identify, select, appraise, and synthesise studies.
T
- T Cell (T Lymphocyte)— A type of white blood cell central to adaptive immunity.
- T-Score (Bone Density)— A comparison of an individual's bone mineral density to the average peak bone density of a healthy young adult.
- Tachyphylaxis— A rapid decrease in the response to a drug after repeated doses over a short period.
- Tendon Healing— The biological repair of damaged tendon tissue, proceeding through inflammatory, proliferative, and remodelling phases over 6-12+ months.
- Tenocyte— A specialised cell type found in tendons that produces and maintains the tendon's collagen-rich extracellular matrix.
- Teratogenicity— The potential of a substance to cause birth defects when administered during pregnancy.
- Terminal Sterilisation— Sterilisation of the final sealed pharmaceutical product, typically by heat (autoclaving) or radiation.
- Tertiary Structure— The three-dimensional shape of a peptide or protein, determined by interactions between amino acid side chains including hydrogen bonds, ionic bonds, hydrophobic interactions, and disulphide bridges.
- Testosterone— The primary male sex hormone, produced mainly by the testes under LH stimulation.
- TGA (Therapeutic Goods Administration)— The Australian regulatory authority responsible for evaluating and monitoring therapeutic goods including medicines, medical devices, and biologicals.
- Therapeutic Drug Monitoring— The practice of measuring drug levels in the blood to optimise dosing — ensuring concentrations remain within the therapeutic window.
- Therapeutic Index— The ratio between the toxic dose and therapeutic dose of a drug.
- Therapeutic Window— The range of drug dosages or blood concentrations that produces effective treatment without unacceptable side effects.
- Thrombocytopenia— An abnormally low platelet count that increases bleeding risk.
- Thymosin Alpha-1— A 28 amino acid peptide involved in T-cell maturation and immune modulation.
- Thymosin Beta-4— A 43 amino acid peptide involved in cell migration, wound healing, and tissue repair through effects on actin polymerisation.
- Thymosins— Small peptides originally isolated from the thymus gland involved in immune development.
- Thyroid C-Cell Tumour— A tumour of the thyroid's parafollicular C-cells, including medullary thyroid carcinoma (MTC).
- Thyroid-Stimulating Hormone (TSH)— A glycoprotein hormone produced by the anterior pituitary that stimulates the thyroid gland to produce thyroid hormones.
- Thyrotropin-Releasing Hormone (TRH)— A 3 amino acid peptide (the smallest known hypothalamic releasing hormone) produced by the hypothalamus that stimulates TSH and prolactin release from the anterior pituitary.
- Tissue Inhibitor of Metalloproteinase (TIMP)— A family of proteins that inhibit matrix metalloproteinases, maintaining the balance between ECM synthesis and degradation.
- Tolerance (Pharmacology)— A gradual decrease in the body's response to a drug with repeated use over time, requiring higher doses to achieve the same effect.
- Topical Administration— Drug delivery applied directly to the skin or mucous membrane for local effect.
- Toxicology— The study of adverse effects of drugs and substances on living organisms.
- Transdermal Delivery— Drug administration through the intact skin into systemic circulation, typically via a patch or specialised formulation.
- Transepidermal Water Loss (TEWL)— The measurement of water evaporating from the skin surface, used as an indicator of skin barrier function.
- Transforming Growth Factor Beta (TGF-β)— A multifunctional growth factor family that regulates cell proliferation, differentiation, immune function, and extracellular matrix production.
- Transgenic Animal Model— An animal that has been genetically modified to carry and express a foreign gene.
- Transplant Rejection— The immune system's attack on a transplanted organ or tissue, recognised as foreign.
- Treatment-Emergent Adverse Event— An adverse event that occurs for the first time or worsens in severity after the start of study treatment.
- Trial Registration— The public documentation of a clinical trial's existence, design, and key information before or shortly after enrolment begins.
- Triple Agonist— A single molecule designed to activate three different receptor types simultaneously.
- Trough Level— The lowest concentration of a drug in the blood, measured just before the next scheduled dose.
- Tumour Necrosis Factor (TNF)— A pro-inflammatory cytokine produced primarily by macrophages that plays central roles in inflammation, immune regulation, and programmed cell death.
- Type 1 Diabetes— An autoimmune disease where the immune system destroys insulin-producing beta cells, requiring lifelong insulin therapy.
- Type 2 Diabetes— A chronic metabolic disease characterised by elevated blood glucose from insulin resistance and declining insulin production.
- Type I Collagen— The most abundant collagen type, comprising approximately 90% of the body's collagen.
- Type II Collagen— The predominant collagen in cartilage, providing resistance to compressive forces in joints.
- Type II Variation (EU)— A significant change to the terms of an existing EU marketing authorisation that requires regulatory assessment before implementation.
- Type III Collagen— A collagen type found in skin, blood vessels, and internal organs that provides structural support and elasticity.
U
- Ubiquitin-Proteasome System— The primary cellular pathway for degrading damaged, misfolded, or unneeded proteins.
- Unblinding— The process of revealing which treatment each participant received, either during a trial (for safety reasons) or at the end of the study for analysis.
- Upregulation— An increase in the number or sensitivity of receptors on a cell surface, typically occurring in response to reduced stimulation or prolonged antagonist exposure.
- USP (United States Pharmacopeia)— The US pharmacopoeia that establishes written and physical reference standards for medicines, dietary supplements, and food ingredients.
- Uterine Fibroids— Benign tumours of the uterine smooth muscle that can cause heavy bleeding, pain, and reproductive problems.
V
- Vascular Endothelial Growth Factor (VEGF)— The primary growth factor stimulating angiogenesis (new blood vessel formation).
- Vasoactive Intestinal Peptide (VIP)— A 28 amino acid neuropeptide found in the gut, pancreas, and nervous system that stimulates intestinal water and electrolyte secretion, relaxes smooth muscle, and has anti-inflammatory properties.
- Vasopressin System— The hormonal system centred on vasopressin (antidiuretic hormone), a 9 amino acid peptide that regulates water balance and blood pressure through V1 and V2 receptors.
- Venom-Derived Peptide— A peptide isolated from or inspired by animal venom (snakes, spiders, scorpions, cone snails, Gila monsters).
- Visceral Adipose Tissue— Fat stored around internal abdominal organs, metabolically active and strongly associated with type 2 diabetes, cardiovascular disease, and metabolic syndrome.
- Volume of Distribution— A pharmacokinetic parameter that describes the theoretical volume into which a drug distributes in the body relative to its plasma concentration.
- von Willebrand Disease— The most common inherited bleeding disorder, caused by deficiency or dysfunction of von Willebrand factor (a protein essential for platelet adhesion).
W
- Waist Circumference— A measurement around the abdomen used as a proxy for visceral fat and central obesity.
- Warning Letter (FDA)— An official FDA communication identifying significant regulatory violations and requesting corrective action.
- Washout Period— A period between treatment phases (particularly in crossover studies) during which no study drug is administered, allowing previous treatment effects to clear from the body.
- Water Content Testing (Karl Fischer)— A titration method for precisely measuring the water content of lyophilised peptide products.
- Weight Regain— The recovery of lost weight after discontinuing a weight management intervention.
- WHO Essential Medicines List— A list published by the World Health Organization identifying the most important medicines needed in a basic health system.
- Withdrawal Effect— Symptoms that occur when a drug is discontinued after prolonged use, caused by the body's physiological adaptation to the drug's presence.
- Wound Healing Phases— The four overlapping stages of tissue repair: haemostasis (blood clotting), inflammation (immune response), proliferation (new tissue formation), and remodelling (tissue maturation).